PolyPid Regains Exclusive European Rights for D-PLEX100

Key Facts

1PolyPid regained exclusive European commercialization rights for D-PLEX₁₀₀ after terminating its 2022 agreement with ADVANZ PHARMA.

2D-PLEX₁₀₀ successfully met primary and secondary endpoints in the Phase 3 SHIELD II trial for preventing surgical site infections.

PolyPid regained exclusive European commercialization rights for D-PLEX₁₀₀ following the termination of its 2022 agreement with ADVANZ PHARMA. Investing.com reported that the partnership was ended by mutual consent, allowing PolyPid to take full control of the drug's commercial path in Europe.

The move follows positive clinical data where D-PLEX₁₀₀ successfully met primary and secondary endpoints in the Phase 3 SHIELD II trial for preventing surgical site infections. Regarding market performance, PYPD closed at $5.37 on October 1, 2026, after trading between a session high of $5.47 and a low of $5.28.